2,5-diisopropyl-benzonitrile | 683231-22-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2,5-diisopropyl-benzonitrile
• 英文别名: 2,5-Di(propan-2-yl)benzonitrile
• CAS: 683231-22-3
• 化学式: C₁₃H₁₇N
• 分子量: 187.285
• InChiKey: RAWSHNDNVMPXMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,5-diisopropyl-benzonitrile 在 氢氧化钾 、 正丁醇 作用下， 生成 2,5-二异丙基-苯甲酸酰胺
  参考文献：
  名称：

  Polyisopropylbenzenes. V. Acetylation¹

  摘要：

  DOI：

  10.1021/ja01252a062
• 作为产物：
  描述：

  1,4-二异丙基苯 在 吡啶 、 四氯化碳 、 溴 、 铁粉 作用下， 生成 2,5-diisopropyl-benzonitrile
  参考文献：
  名称：

  Polyisopropylbenzenes. V. Acetylation¹

  摘要：

  DOI：

  10.1021/ja01252a062

文献信息

• Inhibitors of Ion Channels
  申请人：Marron Brian Edward

  公开号：US20130072471A1

  公开（公告）日：2013-03-21

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了在通过抑制电压门控钠通道中的钠离子流来治疗疾病方面有用的化合物、组合物和方法。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻断与所示条件的发生或复发相关的钠通道来实现。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病性或炎症性疼痛。
• INHIBITORS OF ION CHANNELS
  申请人：Marron Brian Edward

  公开号：US20090143358A1

  公开（公告）日：2009-06-04

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

  本发明提供了化合物、组合物和方法，通过抑制电压门控钠通道中的钠离子流来治疗疾病。更具体地，本发明提供了取代芳基磺酰胺、包含这些化合物的组合物，以及使用这些化合物或组合物治疗中枢或外周神经系统疾病，特别是疼痛和慢性疼痛的方法，通过阻止与所示疾病的发生或复发有关的钠通道。本发明的化合物、组合物和方法特别适用于通过抑制电压门控钠通道中的离子流来治疗神经病理性或炎症性疼痛。
• [EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'INDAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：TYRA BIOSCIENCES INC

  公开号：WO2022147246A1

  公开（公告）日：2022-07-07

  Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.

  本文揭示了与FGFR抑制相关的疾病和/或病症的化合物和治疗方法。
• Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
  申请人：President and Fellows of Harvard College

  公开号：US11040976B2

  公开（公告）日：2021-06-22

  Provided herein are compounds of Formulae (RL), (I), (II), (III), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

  本文提供了式(RL)、(I)、(II)、(III)、(IV)和(V)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同分异构体、立体异构体、原药和同位素标记的衍生物。还提供了涉及本发明化合物的药物组合物、试剂盒和方法，用于治疗代谢紊乱（如糖尿病、高血糖、糖耐量受损、胰岛素抵抗、肥胖）。本发明化合物可作为胰岛素降解酶（IDE）的底物选择性抑制剂。
• Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US11066420B2

  公开（公告）日：2021-07-20

  Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

  蛋白酪氨酸磷酸酶（PTPs）是新陈代谢和胰岛素信号传导的关键调节因子。作为胰岛素信号转导的负调控因子，低分子量蛋白酪氨酸磷酸酶（LMPTP）是胰岛素抵抗及相关疾病的靶标。本文描述了能够调节低分子量蛋白酪氨酸磷酸酶（LMPTP）活性水平的化合物和组合物，以及使用这些化合物和组合物的方法。